Business Context and Reporting Period
Company: Processa Pharmaceuticals, Inc. (PCSA)
Filing Type: Form 8-K (Current Report)
Date of Report: December 12, 2025
Principal Office: Vero Beach, FL
Exchange: Nasdaq Capital Market
Key Financial Metrics
This filing is a corporate action report and does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metrics.
Material Changes
The Company filed a Certificate of Amendment to its Fourth Amended and Restated Certificate of Incorporation to effect a 1-for-25 reverse stock split of its common stock.
- Effective Date: 5:00 p.m. Eastern Time on December 16, 2025.
- Trading Resumption: December 17, 2025, on a split-adjusted basis.
- Symbol: Remains "PCSA".
- CUSIP: New number 74275C403.
- Fractional Shares: No fractional shares issued; holders are rounded up to the nearest whole share.
- Authorized Shares: Remains 1,000,000,000; par value remains $0.0001.
- Adjustments: All outstanding options, warrants, and RSUs will be adjusted proportionally.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook. No specific risks or contingencies are detailed beyond the standard disclosure that the summary is qualified by reference to the full Certificate of Amendment.
Investor Verification Checklist
- Verify the new CUSIP number (74275C403) with your broker to ensure proper trading on December 17, 2025.
- Confirm how the 1-for-25 split ratio applies to any held options, warrants, or restricted stock units.
- Review the treatment of fractional shares if your holding is not evenly divisible by 25 (rounded up to the nearest whole share).
- Check the Company's subsequent filings for any impact on Nasdaq listing compliance requirements.